The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura

Journal of Thrombosis and Thrombolysis

Volumn 27, Issue 3, 2009, Pages 329-333

  Pasa, Semir ^a   Altintas, Abdullah ^a   Cil, Timucin ^a   Danis, Ramazan ^a   Ayyildiz, Orhan ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Anti CD20 monoclonal antibody; Refractory chronic idiopathic thrombocytopenic purpura; Rituximab; Splenectomy

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; PRIORITY JOURNAL; REFRACTORY THROMBOCYTOPENIA; SPLENECTOMY; THROMBOCYTE COUNT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION INDUCTION; SALVAGE THERAPY; SPLENECTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64749110159     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0208-z     Document Type: Article

References (19)

1. Yang R, Han ZC (2000) Pathogenesis and management of chronic idiopathic thrombocytopenic purpura: An update. Int J Hematol 71:18-24
2. Andersson PO, Wadenvik H (2004) Chronic idiopathic thrombocytopenic purpura (ITP): Molecular mechanisms and implications for therapy. Expert Rev Mol Med 6:1-17
3. Zhou Z, Yang R. (2007) Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. Crit Rev Oncol Hematol, doi: 10.1016/j.critrevonc.2007.06.007
4. Braendstrup P, Bjerrum OW, Nielsen OJ et al (2005) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 78:275-280
5. Giagounidis AA, Anhuf J, Schneider P et al (2002) Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: A pilot study. Eur J Haematol 69:95-100
6. Cooper N, Stasi R, Cunningham-Rundles S et al (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125:232-239
7. Peñalver FJ, Jiménez-Yuste V, Almagro M et al (2006) Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 85:400-406
8. Bennett CM, Rogers ZR, Kinnamon DD et al (2006) Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107:2639-2642
9. Stasi R, Pagano A, Stipa E et al (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for chronic idiopathic thrombocytopenic purpura. Blood 98:952-957
10. Stasi R, Stipa E, Forte V et al (2002) Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 99:3872-3873
11. Moschovi M, Trimis G, Pergantou H et al (2005) Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura. J Paediatr Child Health 41:384-386
12. Kojouri K, Vesely SK, Terrell DR et al (2004) Splenectomy for adults patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count response, prediction of response, and surgical complications. Blood 104:2623-2634
13. Kumar S, Diehn FE, Gertz MA et al (2002) Splenectomy for immune thrombocytopenic purpura: Long-term results and treatment of postsplenectomy relapses. Ann Hematol 81:312-319
14. Stasi R, Provan D (2004) Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 79:504-522
15. Vianelli N, Galli M, de Vivo A et al (2005) Efficacy and safety of splenectomy in immune thrombocytopenic purpura: Long-term results of 402 cases. Haematologica 90:4
16. Schwartz J, Leber MD, Gillis S et al (2003) Long-term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 72:94-98
17. Saleh MN, Gutheil J, Moore M et al (2000) A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27:99-103
18. Portielje JE, Westendorp RG, Kluin-Nelemans HC et al (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97:2549-2554
19. Bennett CM, Rogers ZR, Kinnamon DD et al (2006) Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107:2639-2642